Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK-1286 in Advanced Solid Tumors
NCT06779045Phase 1Not yet recruiting
- Sponsor
- Yingli Pharma
- Start
- Feb 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of AK-1286 in solid tumor (advanced stage), sponsored by Yingli Pharma. Primary endpoints: Occurrence of drug limited toxicities at 21 days, Incidence of Treatment-emergent adverse events and serious adverse events up to 60 months and 2 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
AK-1286
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06779045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06779045.